List of Magenta Therapeutics patents

List of Magenta Therapeutics patents

List of Sonos, Inc. patents

List of Probi AB patents

List of VDO (company) patents

CEOs of environmental consulting companies

List of film distribution patents

Patents where

Current Assignee

Name

is

Magenta Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10899843 Compositions and methods for the depletion of CD117+ cells	Patent 10899843 was granted and assigned to Magenta Therapeutics on January, 2021 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10899843	January 26, 2021
	‌ US Patent 10882915 Compositions and methods for the depletion of CD117+ cells	Patent 10882915 was granted and assigned to Magenta Therapeutics on January, 2021 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10882915	January 5, 2021
	‌ US Patent 10111966 Methods for the depletion of CD117+ cells	Patent 10111966 was granted and assigned to Magenta Therapeutics on October, 2018 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10111966	October 30, 2018
	‌ US Patent 11572411 Anti-CD117 antibodies and conjugates		Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	11572411	February 7, 2023
	‌ US Patent 11229711 Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use	Patent 11229711 was granted and assigned to Magenta Therapeutics on January, 2022 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	11229711	January 25, 2022
	‌ US Patent 10434185 Compositions and methods for the depletion of CD137+ cells	Patent 10434185 was granted and assigned to Magenta Therapeutics on October, 2019 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10434185	October 8, 2019
	‌ US Patent 10351572 Aryl hydrocarbon receptor antagonists and uses thereof	Patent 10351572 was granted and assigned to Magenta Therapeutics on July, 2019 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10351572	July 16, 2019
	‌ US Patent 10919900 Aryl hydrocarbon receptor antagonists and uses thereof	Patent 10919900 was granted and assigned to Magenta Therapeutics on February, 2021 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10919900	February 16, 2021
	‌ US Patent 10624973 Methods for the depletion of cells	Patent 10624973 was granted and assigned to Magenta Therapeutics on April, 2020 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10624973	April 21, 2020
	‌ US Patent 10457683 Aryl hydrocarbon receptor antagonists and uses thereof	Patent 10457683 was granted and assigned to Magenta Therapeutics on October, 2019 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10457683	October 29, 2019
	‌ US Patent 10576161 Compositions and methods for the depletion of CD137+ cells	Patent 10576161 was granted and assigned to Magenta Therapeutics on March, 2020 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10576161	March 3, 2020
	‌ US Patent 11260079 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells	Patent 11260079 was granted and assigned to Magenta Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	11260079	March 1, 2022
	‌ US Patent 10058573 Dosing regimens for the mobilization of hematopoietic stem cells	Patent 10058573 was granted and assigned to Magenta Therapeutics on August, 2018 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10058573	August 28, 2018
	‌ US Patent 10781259 Modified antibodies and related compounds, compositions, and methods of use	Patent 10781259 was granted and assigned to Magenta Therapeutics on September, 2020 by the United States Patent and Trademark Office.	Magenta Therapeutics	Magenta Therapeutics		United States Patent and Trademark Office	10781259	September 22, 2020

14 results

0 selected

14 results

0 selected